Xingqi Pharmaceutical's SQ-22031 enrolls first patient in phase II trial

Shenyang Xingqi Pharmaceutical (SZSE:300573) announced that its SQ-22031 eye drops have enrolled the first subject in its Phase II clinical trial for neurotrophic keratitis (NK). The study is a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of SQ-22031 in NK patients. SQ-22031 is a drug developed by the company for the treatment of NK, which can promote the growth and survival of sensory neurons and sympathetic neurons, and restore the function of damaged neurons, which can rapidly heal patients' corneal damage, and improve corneal sensation and lacrimal secretion. The company stated that the trial's progress and outcomes, as well as future market competition, remain uncertain, and investors should exercise caution.